Neurological Surgery 脳神経外科52巻4号

2024年07月発行

特集 髄膜腫の現在—最新の知識を活かした最善の治療のために Ⅵ 最近話題の髄膜腫の未解決問題

髄膜腫に対する薬物療法

著者： 田村亮太¹

所属機関： ¹慶應義塾大学医学部脳神経外科

ページ範囲：P.825 - P.838

Point
・髄膜腫に対する包括的遺伝子解析や微小環境解析の結果，さまざまな分子標的薬や免疫療法の可能性が報告されている．
・未だ顕著な治療効果を示す薬物療法は認めないため，各種併用療法や遺伝子解析に基づく個別化医療の発展が望まれる．
・ウイルス療法や遺伝子療法などの新たな治療戦略の開発にも期待したい．

参考文献

1）Nakamura H, et al：Epidemiological study of primary intracranial tumors：a regional survey in Kumamoto prefecture in southern Japan--20-year study. Int J Clin Oncol 16：314-321, 2011

2）Bi WL, et al：Meningioma Genomics：Diagnostic, Prognostic, and Therapeutic Applications. Front Surg 3：40, 2016　doi:10.3389/fsurg.2016.00040

3）Peyre M, et al：De novo and secondary anaplastic meningiomas：a study of clinical and histomolecular prognostic factors. Neuro Oncol 20：1113-1121, 2018

4）Chen WC, et al：Radiotherapy for meningiomas. J Neurooncol 160：505-515, 2022

5）Goldbrunner R, et al：EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol 17：e383-e391, 2016　doi:10.1016/S1470-2045(16)30321-7

6）Louis DN, et al：The 2021 WHO Classification of Tumors of the Central Nervous System：a summary. Neuro Oncol 23：1231-1251, 2021

7）Seizinger BR, et al：Molecular genetic approach to human meningioma：loss of genes on chromosome 22. Proc Natl Acad Sci U S A 84：5419-5423, 1987

8）Clark VE, et al：Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339：1077-1080, 2013

9）Yuzawa S, et al：Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system. Mod Pathol 29：708-716, 2016

10）James MF, et al：NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol 29：4250-4261, 2009

11）Tamura R：Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis. Int J Mol Sci 22：5850, 2021　doi:10.3390/ijms22115850

12）Brastianos PK, et al：Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 45：285-289, 2013

13）Blankenstein MA, et al：Assay of oestrogen and progestin receptors in human meningioma cytosols using immunological methods. Clin Chim Acta 165：189-195, 1987

14）Grunberg SM, et al：Long-term administration of mifepristone（RU486）：clinical tolerance during extended treatment of meningioma. Cancer Invest 24：727-733, 2006

15）Lamberts SW, et al：Mifepristone（RU 486）treatment of meningiomas. J Neurol Neurosurg Psychiatry 55：486-490, 1992

16）Ji Y, et al：Double-blind phase Ⅲ randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma：SWOG S9005. J Clin Oncol 33：4093-4098, 2015

17）Arena S, et al：Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neurooncol 66：155-166, 2004

18）Simó M, et al：Recurrent high-grade meningioma：a phase Ⅱ trial with somatostatin analogue therapy. Cancer Chemother Pharmacol 73：919-923, 2014

19）Johnson DR, et al：Phase Ⅱ study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma. Neuro Oncol 13：530-535, 2011

20）Gupta S, et al：Medical management of meningioma in the era of precision medicine. Neurosurg Focus 44：E3, 2018　doi:10.3171/2018.1.FOCUS17754

21）Kaley T, et al：Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma：a RANO review. Neuro Oncol 16：829-840, 2014

22）Preusser M, et al：Trabectedin for recurrent WHO grade 2 or 3 meningioma：a randomized phase Ⅱ study of the EORTC Brain Tumor Group（EORTC-1320-BTG）. Neuro Oncol 24：755-767, 2022

23）Barresi V：Angiogenesis in meningiomas. Brain Tumor Pathol 28：99-106, 2011

24）Furtner J, et al：Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade Ⅱ or Ⅲ meningioma. Neuro Oncol 18：401-407, 2016

25）Lou E, et al：Bevacizumab therapy for adults with recurrent/progressive meningioma：a retrospective series. J Neurooncol 109：63-70, 2012

26）Nayak L, et al：Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol 109：187-193, 2012

27）Grimm SA, et al：Phase Ⅱ trial of bevacizumab in patients with surgery and radiation refractory progressive meningioma. J Clin Oncol 33（Suppl）：2055, 2015

28）Kumthekar P, et al：A multi-institutional phase Ⅱ trial of bevacizumab for recurrent and refractory meningioma. Neurooncol Adv 4：vdac123, 2022　doi:10.1093/noajnl/vdac123

29）Kaley TJ, et al：Phase Ⅱ trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol 17：116-121, 2015

mutations in meningiomas. Oncol Lett 7：2019-2022, 2014

31）Norden AD, et al：Phase Ⅱ trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol 96：211-217, 2010

32）Karajannis MA, et al：Phase Ⅱ trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol 14：1163-1170, 2012

33）Papadopoulos N, et al：The PDGF/PDGFR pathway as a drug target. Mol Aspects Med 62：75-88, 2018

34）Black PM, et al：Platelet-derived growth factor expression and stimulation in human meningiomas. J Neurosurg 81：388-393, 1994

35）Candeliere GA, et al：Increased expression of the c-fos proto-oncogene in bone from patients with fibrous dysplasia. N Engl J Med 332：1546-1551, 1995

36）Reardon DA, et al：Phase Ⅱ study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 23：9359-9368, 2005

37）Wen PY, et al：Phase Ⅰ /Ⅱ study of imatinib mesylate for recurrent malignant gliomas：North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12：4899-4907, 2006

38）Shih KC, et al：A phase Ⅱ trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma. J Neurooncol 129：281-288, 2016

39）Graillon T, et al：Combined treatment by octreotide and everolimus：Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas. J Neurooncol 124：33-43, 2015

40）Graillon T, et al：Everolimus and octreotide for patients with recurrent meningioma：results from the phase Ⅱ CEVOREM trial. Clin Cancer Res 26：552-557, 2020

41）Mirian C, et al：Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification：an individual patient data meta-analysis. J Neurol Neurosurg Psychiatry 91：378-387, 2020

42）Spiegl-Kreinecker S, et al：TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma. Neuro Oncol 20：1584-1593, 2018

43）Sievers P, et al：CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathol 140：409-413, 2020

44）von Achenbach C, et al：Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02. Transl Oncol 13：100852, 2020　doi:10.1016/j.tranon.2020.100852

45）Takahashi K, et al：Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131：861-872, 2007

46）Reuss DE, et al：Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol 125：351-358, 2013

47）Clark VE, et al：Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat Genet 48：1253-1259, 2016

48）Abedalthagafi M, et al：Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol 18：649-655, 2016

49）Hyman DM, et al：AKT Inhibition in Solid Tumors With AKT1 Mutations. J Clin Oncol 35：2251-2259, 2017

50）Weller M, et al：Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363. J Natl Cancer Inst 109：1-4, 2017　doi:10.1093/jnci/djw320

51）Youngblood MW, et al：Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas. J Neurosurg 133：1345-1354, 2019

52）Xu J, et al：Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer. Nat Nanotechnol 14：388-397, 2019

53）Shankar GM, et al：Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol 19：535-545, 2017

54）Kaba SE, et al：The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery 40：271-275, 1997

55）Muhr C, et al：Meningioma treated with interferon-alpha, evaluated with［（11）C］-L-methionine positron emission tomography. Clin Cancer Res 7：2269-2276, 2001

56）Chamberlain MC, et al：Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer 113：2146-2151, 2008

57）Iwai Y, et al：Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci 24：26, 2017　doi:10.1186/s12929-017-0329-9

58）Karimi S, et al：Programmed death ligand-1（PD-L1）expression in meningioma；prognostic significance and its association with hypoxia and NFKB2 expression. Sci Rep 10：14115, 2020　doi:10.1038/s41598-020-70514-z

59）Hao S, et al：Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas. J Neurooncol 144：11-20, 2019

60）Karimi S, et al：Clinical significance of checkpoint regulator “Programmed death ligand-1（PD-L1）” expression in meningioma：review of the current status. J Neurooncol 151：443-449, 2021

61）Bi WL, et al：Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma：phase Ⅱ trial results. Neuro Oncol 24：101-113, 2022

62）Brastianos PK, et al：Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. Nat Commun 13：1325, 2022　doi:10.1038/s41467-022-29052-7

63）Dunn IF, et al：Mismatch repair deficiency in high-grade meningioma：a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade. JCO Precis Oncol 2018：PO.18.00190, 2018　doi:10.1200/PO.18.00190

64）Kannapadi NV, et al：Synthesizing Molecular and Immune Characteristics to Move Beyond WHO Grade in Meningiomas：A Focused Review. Front Oncol 12：892004, 2022　doi:10.3389/fonc.2022.892004

65）Garzon-Muvdi T, et al：Basis for Immunotherapy for Treatment of Meningiomas. Front Neurol 11：945, 2020　doi:10.3389/fneur.2020.00945

66）Tamura R, et al：The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment：perspectives for therapeutic implications. Med Oncol 37：2, 2019　doi:10.1007/s12032-019-1329-2

67）Zhao JL, et al：A rare case report of recurrent atypical meningioma with multiple metastases treated with anti-PD-1 and anti-VEGF therapy. BMC Neurol 22：392, 2022　doi:10.1186/s12883-022-02919-4

68）June CH, et al：Chimeric Antigen Receptor Therapy. N Engl J Med 379：64-73, 2018

69）Zheng PP, et al：Approved CAR T cell therapies：ice bucket challenges on glaring safety risks and long-term impacts. Drug Discov Today 23：1175-1182, 2018

70）Yang S, et al：B7-H3, a checkpoint molecule, as a target for cancer immunotherapy. Int J Biol Sci 16：1767-1773, 2020

71）Marofi F, et al：CAR T cells in solid tumors：challenges and opportunities. Stem Cell Res Ther 12：81, 2021　doi:10.1186/s13287-020-02128-1

72）Tamura R：Drug repositioning for refractory benign tumors of the central nervous system. Int J Mol Sci 24：12997, 2023　doi:10.3390/ijms241612997

73）Stupp R, et al：Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma：a randomized clinical trial. JAMA 314：2535-2543, 2015

74）Chen WC, et al：Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Nat Med 29：3067-3076, 2023

75）Alamir H, et al：In situ characterization of stem cells-like biomarkers in meningiomas. Cancer Cell Int 18：77, 2018　doi:10.1186/s12935-018-0571-6

76）Nigim F, et al：A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus. Neuro Oncol 18：1278-1287, 2016

77）Liu TC, et al：Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin Cancer Res 12：6791-6799, 2006

78）Yazaki T, et al：Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res 55：4752-4756, 1995

79）Tamura R, et al：Gene therapy using genome-edited iPS cells for targeting malignant glioma. Bioeng Transl Med 8：e10406, 2023

80）De La Garza-Ramos R, et al：Current standing and frontiers of gene therapy for meningiomas. Neurosurg Focus 35：E4, 2013　doi:10.3171/2013.8.FOCUS13305